Caduet is a fixed-dose combination of Atorvastatin-Amlodipine besylate indicated for patients suffering from both, high blood pressure and high levels of cholesterol.
Ranbaxy Americas senior vice-president and regional director Venkat Krishnan said the launch of Atorvastatin-Amlodipine besylate tablets will further complement its goal to bring high quality, affordable generic medicines to the US healthcare system.
"The introduction of Atorvastatin-Amlodipine besylate tablets is a significant and important addition to our portfolio of cardio-vascular products, in the US,” Krishnan added.